Black Diamond Therapeutics (Black Diamond Therapeutics) EBIT : $-85.15 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Black Diamond Therapeutics EBIT?

Black Diamond Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-20.25 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-85.15 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Black Diamond Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 was -296.94%. Black Diamond Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -347.53%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Black Diamond Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -46.43%.

Black Diamond Therapeutics EBIT Historical Data

The historical data trend for Black Diamond Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Black Diamond Therapeutics EBIT Chart

Black Diamond Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-35.26

-67.25

-126.87

-92.83

-86.46

Black Diamond Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-21.56	-20.03	-24.01	-20.86	-20.25

Competitive Comparison of Black Diamond Therapeutics's EBIT

For the Biotechnology subindustry, Black Diamond Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Black Diamond Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Black Diamond Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Black Diamond Therapeutics's EV-to-EBIT falls into.

Black Diamond Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-85.15 Mil.

Black Diamond Therapeutics (NAS:BDTX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Black Diamond Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-80.984 * ( 1 - 0% )	/	( (27.646	+	26.899)	/ 2 )
=	-80.984	/	27.2725
=	-296.94 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	158.567	-	16.533	-	( 131.4	-	max(0, 19.646	-	134.034	+	131.4	))
=	27.646

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	142.521	-	13.67	-	( 115.199	-	max(0, 16.854	-	118.806	+	115.199	))
=	26.899

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Black Diamond Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-80.984	/	( ( (23.71 + max(-13.899, 0))	+	(22.896 + max(-10.063, 0)) )	/	2 )
=	-80.984	/	( ( 23.71	+	22.896 )	/	2 )
=	-80.984	/	23.303
=	-347.53 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.634)	-	(16.533	+	0	+	0)
=	-13.899

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.607)	-	(13.67	+	0	+	0)
=	-10.063

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Black Diamond Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-85.145	/	183.370
	=	-46.43 %

Black Diamond Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Black Diamond Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Black Diamond Therapeutics (Black Diamond Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Black Diamond Therapeutics Inc (NAS:BDTX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Main Street, 14th Floor, Cambridge, MA, USA, 02142

Website

https://www.blackdiamondtherapeutics.com

Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-189 and BDTX-1535.

Executives

Biotech Growth N V	10 percent owner	ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Ra Capital Nexus Fund, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali Behbahani	director, 10 percent owner	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Peter Kolchinsky	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David M. Epstein	director, officer: See Remarks	OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Sergey Yurasov	officer: CHIEF MEDICAL OFFICER	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E., SUITE 310, SEATTLE WA 98102
Elizabeth Buck	officer: CHIEF SCIENTIFIC OFFICER	C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Erika Jones	officer: SEE REMARKS	C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Fang Ni	officer: SEE REMARKS	C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Biotech Ag Bb	10 percent owner	SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Wendy L Dixon	director
Mark A. Velleca	director	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Brent Hatzis-schoch	officer: See Remarks	C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451